A recent original investigation1 hints at a possible benefit of combining 2 drugs for the treatment of asthma. The study was sponsored by a pharmaceutical company, and 5 of the 8 authors were employed by that company. One of the drugs under investigation was manufactured by that company, and the generic and trade name were given; it was also called potent. The other drug manufactured by another company received no such accolade and was only mentioned by its generic name. It is difficult to assume an oversight.